1
Robin Clark, Anthony Davies: Baculovirus expression system and method for high throughput expression of genetic material. Onyx Pharmaceuticals, Gregory Giotta, May 1, 2001: US06225060 (118 worldwide citation)

The present invention provides novel recombinant baculovirus expression systems for expressing foreign genetic material in a host cell. Such expression systems are readily adapted to an automated method for expression foreign genetic material in a high throughput manner. In other aspects, the presen ...


2
Robin Clark, Joanna Albala, Ian McConnell, Ken Franke: Selection method for producing recombinant baculovirus. Onyx Pharmaceuticals, Gregory Giotta, August 6, 2002: US06428960 (85 worldwide citation)

The present invention provides a novel method for producing recombinant baculoviruses expressing genes of interest by inserting a selectable marker gene, specifically the puromycin resistance (pac) gene, adjacent to the gene of interest into the baculovirus genome, and selecting for viruses that exp ...


3

4
James R Erickson, Scott Powers: Reverse two-hybrid method. ONYX Pharmaceuticals, Gregory Giotta, Tracy Dunn, June 11, 1996: US05525490 (49 worldwide citation)

The reverse two-hybrid method has been designed to provide a practical and efficient means of utilizing yeast cell-based assays to screen for molecules that can inhibit protein-protein interactions of interest. Existing two-hybrid systems involve reconstitution in yeast of a transcriptional activato ...


5
Ellen Freed, Rosamaria Ruggieri: Interaction of RAF-1 and 14-3-3 proteins. Onyx Pharmaceuticals, Cooley Godward Castro Huddleson & Tatum, January 28, 1997: US05597719 (47 worldwide citation)

Intermolecular interactions between Raf-1 and human 14-3-3 proteins which regulate Raf activity are identified. Compositions and method for identifying novel drugs which modulate Raf activity in vivo are provided.


6
Francis McCormick: Cytopathic viruses for therapy and prophylaxis of neoplasia. ONYX Pharmaceuticals, Gregory Giotta, Timothy E Torchia, October 14, 1997: US05677178 (44 worldwide citation)

Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able t ...


7
James R Bischoff, Maria J Fernandez Sarabia: Bcl-2 and R-ras complex. Onyx Pharmaceuticals, Gregory Giotta, Tracy Dunn, July 23, 1996: US05539085 (33 worldwide citation)

The invention provides compositions and methods for screening for agents which are modulators of bcl-2 function and can modulate bcl-2-mediated apoptosis and/or modulate neoplastic and immune conditions dependent upon bcl-2 function. The invention also provides a composition comprising a substantial ...


8
Francis McCormick: Cytopathic viruses for therapy and prophylaxis of neoplasia. Onyx Pharmaceuticals, Gregory J Giotta, Nina M Ashton, September 1, 1998: US05801029 (30 worldwide citation)

Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able t ...


9
Francis McCormick: Cytopathic viruses for therapy and prophylaxis of neoplasia. ONYX Pharmaceuticals, Gregory J Giotta Ph D, December 8, 1998: US05846945 (29 worldwide citation)

Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able t ...


10
Francis McCormick: Cytopathic viruses for therapy and prophylaxis of neoplasia. Onyx Pharmaceuticals, Gregory Giotta, January 5, 1999: US05856181 (19 worldwide citation)

Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able t ...